ArticleCancers2022
Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis.Biomarkers in medicine · 2025Pooled it
- Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.Cancer immunology, immunotherapy : CII · 2023Pooled it
- Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.Nature communications · 2025Trial
- Mechanisms of Resistance to ALK Inhibitors and Corresponding Treatment Strategies in Lung Cancer.International journal of general medicine · 2025Review
- Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies.MedComm · 2024Review
- Article
- Alectinib continuation beyond progression inTranslational lung cancer research · 2024Article
- Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer andFrontiers in oncology · 2024Article
- Anaplastic lymphoma kinase inhibitors-a review of anticancer properties, clinical efficacy, and resistance mechanisms.Frontiers in pharmacology · 2023Review
- Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.Journal of translational medicine · 2022Article
- Generative AI - Assisted Adaptive Cancer Therapy.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 9 institutions in 1 country.
Satoshi WatanabeDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.ORCID 0000-0003-0041-6981
Kazuko SakaiDepartment of Genome Biology, Kindai University Faculty of Medicine, Osaka 589-8511, Japan.
Naoya MatsumotoDepartment of Respiratory Medicine, Nishiniigata Chuo National Hospital, Niigata 951-8510, Japan.
Jun KoshioDepartment of Respiratory Medicine, Nagaoka Red Cross Hospital, Nagaoka 940-2085, Japan.
Akira IshidaDepartment of Respiratory Medicine, Nagaoka Red Cross Hospital, Nagaoka 940-2085, Japan.
Tetsuya AbeDepartment of Respiratory Medicine, Niigata City General Hospital, Niigata 951-8510, Japan.
Daisuke IshikawaDepartment of Respiratory Medicine, Niigata Prefectural Shibata Hospital, Niigata 951-8510, Japan.
Tomohiro TanakaDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.
Ami AokiDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.
Tomosue KajiwaraDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata 951-8510, Japan.
Kenichi KoyamaDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata 951-8510, Japan.
Satoru MiuraDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata 951-8510, Japan.ORCID 0000-0001-7868-6661
Yuka GotoDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.
Tomoki SekiyaDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.
Ryo SuzukiDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.
Kohei KushiroDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.
Toshiya FujisakiDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.
Naohiro YanagimuraDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.
Aya OhtsuboDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.
Satoshi ShojiDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.
Koichiro NozakiDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.
Yu SaidaDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.
Hirohisa YoshizawaDepartment of Respiratory Medicine, Niigata Medical Center, Niigata 951-8510, Japan.
Kazuto NishioDepartment of Genome Biology, Kindai University Faculty of Medicine, Osaka 589-8511, Japan.ORCID 0000-0002-8275-0846
Toshiaki KikuchiDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.ORCID 0000-0001-7428-1245
Niigata University · JPNiigata Cancer Center Hospital · JPKindai University · JPNagaoka Red Cross Hospital · JPNagara Medical Center · JPNiigata City General Hospital · JPNiigata Prefectural Central Hospital · JPNiigata Prefectural Shibata Hospital · JPNishi Niigata Chuo National Hospital · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic lymphoma kinase (
Indexed as
alectinibanaplastic lymphoma kinase (ALK)bevacizumabctDNAnon-small-cell lung cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.